Dose Insider / Glossary / Pemvidutide

PemvidutideWhat it is and what its liver trials showed

Updated November 20, 2026 路 3 min read 路 IMPACT (Lancet 2025), J Hepatol 2025, DailyMed

Pemvidutide is an experimental weekly injection from Altimmune that activates two receptors, GLP-1 and glucagon, the same pairing as survodutide and mazdutide. It has been tested mainly for fatty liver disease.

58%Pemvidutide 1.2 mg, resolution of MASH by week 24
Resolution of MASH by week 24IMPACT trial, % of patientsPemvidutide 1.2 mg58%Pemvidutide 1.8 mg52%Placebo20%Resolution of MASH by week24IMPACT trial, % of patientsPemvidutide 1.2 mg58%Pemvidutide 1.8 mg52%Placebo20%

Scarring improved in 33% to 36%, against 28%, not a clear difference.

On this page

In the 24-week results of its phase 2b trial in MASH, the inflammatory form of the disease, MASH resolved in 58% on 1.2 mg and 52% on 1.8 mg, against 20% on placebo. We found no label for it on DailyMed on November 20, 2026.1,2

What it is

A 2025 trial report in the Journal of Hepatology describes pemvidutide as a GLP-1 and glucagon dual receptor agonist.3 Pairing GLP-1 with glucagon, whose main target is the liver, makes liver fat and liver inflammation natural places to test it. In the trials described here it was injected under the skin once a week, and in IMPACT it was given without a dose climb, starting at the full dose.1

The liver fat trial

The earlier trial enrolled 94 adults with a body mass index of 28 or more and liver fat of at least 10% on MRI, 29% of whom had type 2 diabetes. They took pemvidutide 1.2, 1.8 or 2.4 mg, or placebo, for 12 weeks.3

J Hepatol 2025.3

IMPACT, the MASH trial

IMPACT is a 48-week phase 2b trial in people with biopsy-confirmed MASH and moderate to advanced scarring, stage F2 or F3, at 83 sites in the United States and Australia. Of 1,557 people screened, 212 were assigned in a 1:2:2 ratio to placebo, 1.2 mg or 1.8 mg. The published results cover week 24.1

Noureddin et al., 2025.1

Starting at the full dose

IMPACT gave pemvidutide at its full dose from the first injection, without the step-by-step climb that the approved GLP-1 medicines use to soften stomach side effects. Adverse events were more common on the drug, at 78% and 81% against 67% on placebo, though most were mild or moderate.1 Whether a climb would be needed in wider use is one of the questions later trials will answer.

How to read the results

Like other drugs of this kind, pemvidutide cleared liver inflammation faster than it reversed scarring, at least by week 24. The same pattern appeared in the tirzepatide trial SYNERGY-NASH, where the effect on MASH resolution was large and the effect on scarring smaller.4 Wegovy, which has a label for this condition, improved both in its 72-week trial: MASH resolved in 63% against 34%, and scarring improved in 37% against 22%.5 IMPACT's full 48-week results will show whether scarring catches up.

Limits

IMPACT was funded by Altimmune, the developer, and several authors of the earlier trial work for the company. Both trials are short: 12 weeks for liver fat and 24 weeks for the published IMPACT results. Pemvidutide is a trial medicine without a U.S. label.1,2 Our page on nausea on a GLP-1 covers the most common side effect of the class.

Sources

  1. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025;406:2644-2655. Funded by Altimmune; NCT05989711. doi:10.1016/S0140-6736(25)02114-2
  2. DailyMed, U.S. National Library of Medicine. Search for "pemvidutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  3. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol 2025;82:7-17. Several authors are affiliated with Altimmune. doi:10.1016/j.jhep.2024.07.006
  4. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. doi:10.1056/NEJMoa2401943
  5. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov

Related analyses

Log any GLP-1 medicine you take with your liver test results over time.

Open Dose Insider